Abstract
| Original language | Undefined/Unknown |
|---|---|
| Pages (from-to) | 579-584 |
| Number of pages | 6 |
| Journal | BJU International |
| Volume | 119 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 1 2017 |
Keywords
- outcomes, PD-1 inhibitors, PD-L1 inhibitors, post-progression therapy, Urothelial carcinoma
Cite this
Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy. / Sonpavde, Guru; Pond, Gregory R.; Mullane, Stephanie; Ramirez, Ana A.; Vogelzang, Nicholas J.; Necchi, Andrea; Powles, Thomas; Bellmunt, Joaquim.
In: BJU International, Vol. 119, No. 4, 01.04.2017, p. 579-584.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Outcomes in patients with advanced urothelial carcinoma after discontinuation of programmed death (PD)-1 or PD ligand 1 inhibitor therapy.
AU - Sonpavde, Guru
AU - Pond, Gregory R.
AU - Mullane, Stephanie
AU - Ramirez, Ana A.
AU - Vogelzang, Nicholas J.
AU - Necchi, Andrea
AU - Powles, Thomas
AU - Bellmunt, Joaquim
PY - 2017/4/1
Y1 - 2017/4/1
N2 - OBJECTIVE: To study the subsequent therapy and disease outcomes of patients with advanced urothelial carcinoma (UC) after discontinuation of programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors. PATIENTS AND METHODS: We performed a retrospective analysis to examine outcomes and systemic therapy administration after PD-1/PD-L1 inhibitor therapy in patients with advanced UC. Data on demographics and therapy administered were collected from the institutions involved in the study. Univariable Cox regression analyses were performed to examine the clinical factors potentially associated with overall survival (OS) after PD-1/PD-L1 inhibitor therapy. RESULTS: Data from 62 patients were available from four institutions, with capture of subsequent therapy and outcomes after checkpoint inhibitor immunotherapy. The median patient age was 65.5 years and 51 patients (82.3 were male. The median (range) duration of
AB - OBJECTIVE: To study the subsequent therapy and disease outcomes of patients with advanced urothelial carcinoma (UC) after discontinuation of programmed death-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitors. PATIENTS AND METHODS: We performed a retrospective analysis to examine outcomes and systemic therapy administration after PD-1/PD-L1 inhibitor therapy in patients with advanced UC. Data on demographics and therapy administered were collected from the institutions involved in the study. Univariable Cox regression analyses were performed to examine the clinical factors potentially associated with overall survival (OS) after PD-1/PD-L1 inhibitor therapy. RESULTS: Data from 62 patients were available from four institutions, with capture of subsequent therapy and outcomes after checkpoint inhibitor immunotherapy. The median patient age was 65.5 years and 51 patients (82.3 were male. The median (range) duration of
KW - outcomes, PD-1 inhibitors, PD-L1 inhibitors, post-progression therapy, Urothelial carcinoma
U2 - 10.1111/bju.13674
DO - 10.1111/bju.13674
M3 - Articolo
VL - 119
SP - 579
EP - 584
JO - BJU International
JF - BJU International
SN - 1464-4096
IS - 4
ER -